Brain Tumor Drugs Market Size, Share, Growth Outlook, Key Trends, Feasibility Scope, New Innovations, Drivers and Demand Forecast by 2023 to 2033

BySanket Badgujar
Market Research

The Brain Tumor Drugs Market refers to the pharmaceutical industry segment focused on the development, production, and sale of drugs used for the treatment of brain tumors. Brain tumors are abnormal growths of cells in the brain that can be either cancerous (malignant) or non-cancerous (benign). They can cause various symptoms and can be life-threatening.

The brain tumor drugs market has seen significant advancements and innovations in recent years, with the aim of improving patient outcomes and prolonging survival rates. Treatment options for brain tumors typically include surgery, radiation therapy, and chemotherapy. However, drug therapies play a crucial role in managing brain tumors, particularly for those that cannot be surgically removed or in cases of recurring tumors.

Get Recently Updated Report of Market as Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16725

From 2023 to 2033, the market for medications for brain tumours is anticipated to grow at a 9.2% CAGR. Market value is anticipated to reach US$ 2.65 billion in 2023 and US$ 6.30 billion in 2033. Nanoparticles are utilized to deliver medications in combination straight to cancer cells or into tumors. This method has also resulted in a reduction in medicine dosage, increased shelf life, and reduced toxicity. A few nano drugs are proven to be effective in crossing the blood-brain barrier, which has been a substantial obstacle in the treatment of brain malignancies.

A brain tumor is an abnormal mass of tissue in which brain cells grow and replicate in an uncontrollable and fast manner. Brain cancers are classified into two types: primary brain tumors and metastatic brain tumors. Primary brain tumors are those that arise from the brain’s tissues or its surrounding tissues. Pharmaceutical businesses have improved supply chain management, which has increased research and development and investment in quality control and manufacturing.

Key Takeaways

  • The brain tumor drugs market is expected to record a CAGR of 9.2% during the forecast period 2023 to 2033.
  • The primary drivers of the market are an increase in brain cancer prevalence, the presence of promising pipeline candidates, and an increased need for precision and customized treatment to drive market expansion.
  • North America dominated the brain tumor drugs market.

Key Development in the Brain Tumor Drugs Market

  • April 2021 – MindMed and Nextage Therapeutics signed a Memorandum of Understanding (MOU) to maximize the administration of selected psychedelic drug candidates using Nextage’s unique Brain Targeting Liposome System (BTLS) delivery technology.
  • March 2021 – Roche and GenMark Diagnostics signed a comprehensive merger agreement for Roche to entirely acquire GenMark for US$ 24.05 per share in an all-cash transaction.
  • September 2022 – F. Hoffmann-La Roche Ltd. announced an agreement to acquire Good Therapeutics. With this acquisition, the firm gains access to Good Therapeutic’s platform technology, which is relevant to a wide range of sectors such as cancer, autoimmune illnesses, metabolic disease, and pain management.
  • June 2022 – Novartis AG received the United States FDA approval for Tafinlar + Mekinist for the treatment of paediatric and adult patients with solid cancers containing the BRAF V600E mutation. BRAF mutations are responsible for tumor growth in over 20 different tumor types, including brain, thyroid, and others.
  • November 2021 – Pfizer Inc. purchased Trillium Therapeutics, a clinical-stage immuno-oncology startup focused on creating novel cancer medicines.

Competitive Landscape:

Prominent Participants in the Market

  • AstraZeneca plc
  • Johnson & Johnson Inc
  • Merck & Co
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • Y-mAbs Therapeutics, Inc
  • Shimadzu Corporation
  • Bristol-Myers Squibb
  • Bayer AG
  • Reddy’s Laboratories Ltd
  • Among others

Key Segment

By Therapy:

  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Others

By Indication:

  • Pituitary
  • Meningioma
  • Glioma
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail & Online Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East and Africa